Glen Lutchman

Publication Details

  • Pilot study of interferon gamma for chronic hepatitis C JOURNAL OF HEPATOLOGY Soza, A., Heller, T., Ghany, M., Lutchman, G., Liang, T. J., Germain, J., Hsu, H. H., Park, Y., Hoofnagle, J. H. 2005; 43 (1): 67-71


    Currently, there are no effective therapies available for patients with chronic hepatitis C who have failed to respond to optimal interferon alfa-based regimens. The aims of this pilot study were to assess the antiviral activity and safety of interferon gamma in chronic hepatitis C.Patients with chronic hepatitis C, genotype 1, who had not responded to or who had relapsed after therapy with interferon alfa and ribavirin were enrolled in a trial of interferon gamma 1b given in doses of 100, 200 or 400 microg subcutaneously three times weekly for 4 weeks. Frequent blood samples were obtained for HCV RNA levels.Fourteen patients were enrolled. Geometric mean HCV RNA levels remained unchanged. Serum aminotransferase levels also did not change, while there were significant decreases in neutrophil counts (-41% from baseline) and hematocrit (-5%). Low grade fever and malaise were common with the first injection of interferon gamma, but no serious side effects were encountered.Although relatively well tolerated, interferon gamma in doses of 100-400 microg thrice weekly had no effect on HCV RNA levels in patients with chronic hepatitis C who had failed to achieve a sustained response to interferon alfa-based therapies.

    View details for DOI 10.1016/j.jhep.2005.02.023

    View details for Web of Science ID 000230282300014

    View details for PubMedID 15913831

Stanford Medicine Resources:

Footer Links: